mRNA-Based CAR Cell Platform

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Traditional CAR-T cell therapies have revolutionized cancer treatment by engineering T cells to recognize and target cancer-specific antigens. However, these therapies have faced challenges related to safety, efficacy, and manufacturing. mRNA-based CAR technology has emerged as a promising alternative, offering several distinct advantages.

One of the key differentiators of mRNA-based CAR technology is its nonviral nature. Unlike traditional CAR-T therapies, which rely on viral vectors to deliver genetic material into T cells, mRNA-based CAR therapy utilizes modified mRNA molecules. These mRNA molecules are engineered to transiently express the CAR on the T cell surface, without permanently altering the host genome.

Introduction to Nonviral mRNA CAR Technology

Within our laboratory, we have established a safer approach to cell therapy through the transient expression and non-viral delivery of one or more mRNA molecules into peripheral blood mononuclear cells (PBMCs) or isolated immune cells, including T cells or NK cells. Typically, we employ electroporation to introduce mRNA encoding CAR/TCR targeting specific tumor antigens into various cell lines. In comparison to cDNA, mRNA exhibits superior transfection efficiency while exerting minimal impact on cell viability.

Fig. 1 The Workflow of Nonviral mRNA-Based CAR/TCR Immune Cell Platform.

Workflow of mRNA-Based CAR Cell Platform

Workflow of mRNA-Based CAR Cell Platform. (Creative Biolabs Original)

Features of mRNA-Based CAR Cell Platform

Enhanced Safety
Nonviral mRNA technology reduces the risk associated with viral vectors, making the therapy safer for patients.
Broader Applicability
The mRNA-Based CAR cell platform's flexibility allows for the development of CAR T-cell therapies targeting a wide range of antigens, broadening the scope of treatable diseases.
Reduced Manufacturing Complexity
The simplified workflow and reduced regulatory burden associated with nonviral mRNA technology streamline the production process, making it more cost-effective.

Case Study

mRNA encoding anti-CD19 CAR was transfected into PBLs or PBMCs. Cells were cryopreserved and thawed for in vitro studies. The expression of CAR can be detected in vitro for about 6-10 days, at the same time, with the expansion of cells, the expression of CAR also gradually decreased. Furthermore, results in animal cancer models suggest that CAR mRNA can safely further control disease progression and prolong survival rate.

Fig. 3 Expression Levels of GFP or CD19-CAR Proteins in T Cells Electroporated with DNA or mRNA.

Fig. 4 Biodistribution Analysis of CAR-mRNA-hCD19 Cells Following Intraperitoneal (i.p.) Injection in a Mice Model.

Creative Biolabs is specialized in designing and performing high-quality custom nonviral mRNA-based CAR/TCR cells analysis services, with different formats or parameters, to satisfy any specific requirement at the most competitive price.

For more detailed information, please feel free to contact us for more information and a detailed quote.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION